Benefit of alosetron in diarrhea-predominant IBS

Results of a controlled trial of 647 women with irritable bowel syndrome (IBS) that was either diarrhea-predominant or had alternating diarrhea and constipation. The women were randomly assigned to alosetron (1 mg twice daily) or placebo for 12 weeks. A significantly greater proportion of women treated with alosetron (41 verses 29 percent with placebo) described adequate relief for all three months of therapy. This difference disappeared with cessation of therapy.